



| 货号 | MS870039 |
|---|---|
| 品牌 | abinScience |
| 描述 |
InVivo Plus Anti-Mouse CD279/PDCD1/PD1 Antibody (RMP1-14) [RMP1-14] (MS870039) is a rat monoclonal antibody detecting Programmed cell death protein 1 in in vivo blocking of PD-1/PD-L signaling. Suitable for Mouse.
|
| 种属反应性 | Mouse |
| 应用 | in vivo blocking of PD-1/PD-L signaling |
| 宿主 | Rat |
| 同种型 | IgG2a, kappa |
| 克隆号 | RMP1-14 |
| 克隆类型 | Monoclonal |
| 靶标 | Programmed cell death protein 1, Protein PD-1, mPD-1, CD279, Pdcd1, Pd1 |
| 内毒素水平 | <1 EU/mg |
| 纯度 | >95% as determined by SDS-PAGE. |
| 相关产品 | pH 7.4 Dilution Buffer |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| Accession号 | Q02242 |
| RRID | InVivo Plus Anti-Mouse PD-1 Antibody(RMP1-14) (abinScience Cat# MS870039, RRID:AB_3722748) |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 背景 | Programmed cell death protein 1 (CD279/PD-1) is a ~31 kDa protein. Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands, such as CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with TCR-CD3 in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival. CD279 is the therapeutic target of pembrolizumab (Keytruda) and nivolumab (Opdivo). 1. Nishimura, H. et al. (1999) Immunity 11, 141-51. PMID: 10485649 2. Nishimura, H. et al. (2001) Science (New York, N.Y.) 291, 319-22. PMID: 11209085 3. Okazaki, T. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 13866-71. PMID: 11698646 4. Okazaki, T. et al. (2011) The Journal of experimental medicine 208, 395-407. PMID: 21300912 5. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443 6. Latchman, Y. et al. (2001) Nature immunology 2, 261-8. PMID: 11224527 7. Lin, DY. et al. (2008) Proceedings of the National Academy of Sciences of the United States of America 105, 3011-6. PMID: 18287011 8. Lázár-Molnár, E. et al. (2008) Proceedings of the National Academy of Sciences of the United States of America 105, 10483-8. PMID: 18641123 9. Yokosuka, T. et al. (2012) The Journal of experimental medicine 209, 1201-17. PMID: 22641383 |
| Note | For research use only. |

SDS-PAGE for InVivo Plus Anti-Mouse CD279/PDCD1/PD1 Antibody (RMP1-14).

Mice treatment with RMP1-14 significantly reduced tumor growth compared with the Rat IgG2a isotype control (RF533109), as shown by lower tumor volumes during the observation period.





24小时产品查询

扫一扫关注我们

专属渠道经理